Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2022 Filed Jun 1, 2022 21:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,311 | $244.41 | $320,421.51 |
DisclosureSEC source: 0001127602-22-016215 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,711 Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 24,042 | $244.41 Strike: $244.41 | $5,876,105.22 |
DisclosureSEC source: 0001127602-22-016215 · form4.xml · derivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,042 Underlying: Common Stock · 24,042 shares Expires 2032-05-27 F1 · shares: Stock Options vest as follows: 6,010 on May 27, 2023, 6,011 on May 27, 2024, 6,010 on May 27, 2025 and 6,011 on May 27, 2026. Read SEC document |
| February 23, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,770 | $289.58 | $512,556.60 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,022 Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,296 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · derivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,296 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 352 | $295.70 | $104,084.85 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,022 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F14 · price: This transaction was executed in multiple trades at prices ranging from $295.54 to $296.4. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 389 | $294.70 | $114,636.86 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,374 F13 · date: This transaction was executed in multiple trades at prices ranging from $294.47 to $294.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 325 | $293.81 | $95,488.84 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,763 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $293.56 to $294.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 746 | $292.87 | $218,478.48 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,088 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $292.58 to $293.205. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 981 | $291.81 | $286,262.67 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,834 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $291.505 to $291.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,259 | $291.05 | $366,436.48 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,815 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $290.55 to $291.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,078 | $290.01 | $312,632.94 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,074 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $289.59 to $290.435. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 805 | $288.82 | $232,500.91 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,152 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $288.45 to $289.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,245 | $287.84 | $1,221,888.87 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,957 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $287.445 to $288.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,171 | $287.10 | $910,388.39 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,202 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $286.615 to $287.435. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,027 | $286.06 | $579,844.63 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,373 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $285.48 to $286.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,415 | $284.79 | $972,542.48 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,400 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $284.45 to $285.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,503 | $283.89 | $426,683.06 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,815 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $283.445 to $284.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 20,296 | $109.34 | $2,219,164.64 |
DisclosureSEC source: 0001127602-22-006781 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 17,436 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · derivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,436 Underlying: Common Stock · 17,436 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 350 | $292.74 | $102,460.02 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,792 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $292.51 to $292.845. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $291.50 | $29,150.00 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,142 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,481 | $290.89 | $430,801.72 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,242 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $290.46 to $291.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,600 | $290.03 | $754,085.28 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,723 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $289.56 to $290.385. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,472 | $288.86 | $1,291,763.14 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,323 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $288.41 to $289.385. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5,243 | $288.12 | $1,510,587.99 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,795 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $287.55 to $288.4. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,394 | $286.93 | $686,919.28 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,038 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $286.59 to $287.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 796 | $285.88 | $227,560.80 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,432 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $285.41 to $286.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 17,436 | $144.67 | $2,522,466.12 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,610 | $293.61 | $472,712.10 |
DisclosureSEC source: 0001127602-22-006351 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,792 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 15 | $334.06 | $5,010.90 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,402 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 236 | $333.29 | $78,656.72 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,417 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F20 · price: This transaction was executed in multiple trades at prices ranging from $332.89 to $333.3575. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 51 | $332.63 | $16,964.13 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,653 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 914 | $331.43 | $302,930.77 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,704 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F19 · price: This transaction was executed in multiple trades at prices ranging from $331.03 to $331.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 465 | $330.16 | $153,525.98 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,618 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F18 · price: This transaction was executed in multiple trades at prices ranging from $329.835 to $330.495. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 158 | $329.12 | $52,001.12 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,083 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F17 · price: This transaction was executed in multiple trades at prices ranging from $328.79 to $329.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 98 | $328.50 | $32,193.37 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,241 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F16 · price: This transaction was executed in multiple trades at prices ranging from $328.36 to $328.7025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 179 | $326.88 | $58,511.14 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,339 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F15 · price: This transaction was executed in multiple trades at prices ranging from $326.825 to $327.055. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 174 | $323.07 | $56,213.85 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,518 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F14 · price: This transaction was executed in multiple trades at prices ranging from $322.9 to $323.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $321.93 | $32,193.00 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,692 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 420 | $320.23 | $134,495.59 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,792 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F13 · price: This transaction was executed in multiple trades at prices ranging from $319.8175 to $320.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 325 | $317.98 | $103,344.28 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,212 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $317.83 to $318.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,243 | $317.06 | $394,102.97 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,537 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $316.765 to $317.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,157 | $316.34 | $682,353.36 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,780 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $315.79 to $316.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,816 | $315.15 | $572,314.03 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,937 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $314.78 to $315.605. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,812 | $314.43 | $884,179.41 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,753 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $313.785 to $314.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,514 | $313.24 | $474,244.60 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,565 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $312.86 to $313.745. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,835 | $312.19 | $572,871.77 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,079 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $311.76 to $312.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,643 | $311.30 | $511,465.74 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,914 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $310.8475 to $311.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,456 | $310.35 | $762,226.48 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,557 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $309.84 to $310.735. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,064 | $309.36 | $329,164.25 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,013 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $308.75 to $309.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.